14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ABUS vs SNYR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABUS carries a Unified Composite Score of 43.4/100 (HOLD) at $4.02 (10.2x Forward P/E, 80.1% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin).
Composite vs. Pillar Nuance: While SNYR currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ABUS 43.4/100 HOLD), ABUS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (80.1% vs. -10.3% operating margin) and revenue trajectory (-43.5% vs. -32.8% YoY).
Competes within the Medical Distribution value chain with $4.1M market capitalization and -10.3% operating margin.
OpEx & R&D Reinvestment75.7% of Rev ($21M)
90D Engineering Disclosures0 Published
Investor FAQ ABUS vs SNYR Key Questions & Quantitative Answers
As of Nov 20, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABUS carries a Unified Composite Score of 43.4/100 (HOLD) at $4.02 (10.2x Forward P/E, 80.1% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin). Composite vs. Pillar Nuance: While SNYR currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ABUS 43.4/100 HOLD), ABUS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (80.1% vs. -10.3% operating margin) and revenue trajectory (-43.5% vs. -32.8% YoY).
ABUS leads the Growth & Scale pillar: ABUS posts -43.5% YoY revenue growth and +0.0% YoY earnings growth on $181M TTM revenue (91.9% gross margin, 80.1% operating margin), compared with SNYR at -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ABUS cumulative revenue shifted +0.0% while SNYR shifted +0.0%. In operating R&D and SG&A reinvestment, ABUS deploys 11.8% of Rev ($21M) (0 90-day corporate R&D disclosures) versus 75.7% of Rev ($21M) (0 disclosures) for SNYR.
SNYR screens cheaper on headline valuation multiples. ABUS trades at 10.2x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (unreported FCF margin), whereas SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABUS (269.6% ROE) versus SNYR (-361.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ABUS carries 133.2% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 48% Vol realized risk). By comparison, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.